Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-68284528 CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
2018-000121-32Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ciltacabtagene autoleucel in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants with Adverse Events (Phase 1b). Started May 2019; status: terminated.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-000121-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000121-32.